Anticoagulant Circulant Ressemblant à l’Antithrombine VI au cours d’un Lupus Érythémateux Disséminé

Résumé

Nous avons décrit le cas d’une malade atteinte de diathèse hémorragique au cours d’un lupus érythémateux.

L’étude de la coagulation sanguine dans ce cas a indiqué aucune anomalie, mis a part une thrombocytopénie modérée, une augmentation de l’activité fibrinolytique et un allongement du temps de thrombine.

Nous avons demontré la présence d’un inhibiteur de la thrombine ressemblant à l’antithrombine VI, antithrombine produite au cours de la dégradation protéolytique du fibrinogène.

Nous avons comparé cette antithrombine avec les autres inhibiteurs de la coagulation apparissants au cours de LE et décrits dans la littérature. L’influence du traitement par les hormones surrénales sur la fibrinolyse et sur disparition de l’antithrombine VI est discutée.

• Bibliographie

• (1) Bar-Pratkowska J, Niewiarowska M. O aktywnosci fibrynolizy w przypadku przedwczesnego odklejenia iozyska. Pol. Tyg. lek. 13: 1908 1958;
• (2) Biggs R, Douglas A. S. The thromboplastin generation test. J. clin. Path. 6: 23 1953;
• (3) Bonnin J. A, Cohen A. K, Hicks N. D. Coagulation defects in a case of systematic lupus erythematosus with thrombocytopenia. Brit. J. Haemat. 2: 168 1956;
• (4) Conley C. L, Hartmann R. C. A haemorrhagic disorder caused by circulating anticoagulant in patients with disseminated lupus erythematosus. J. clin. Invest. 31: 621 1952;
• (5) Cottier P, Leupold R, Schellin W. Die hämorrhagische Diathese des Prostatakarzinoms und ihre Behandlung. Schweiz. med. Wschr. 85: 781 1955;
• (6) Crosby W. H, Stefanini M. Pathogenesis of the plasma transfusion reaction with special reference to the blood coagulation system. J. Lab. clin. Med. 40: 374 1952;
• (7) Dubois E. L. The effect of the LE cell test on the clinical picture of systemic lupus erythematosus. Ann. intern. Med. 38: 1265 1953;
• (8) Duckert F, Flückiger P, Isenschmied H, Matter M, Vogel-Meng J, Koller F. A modification of the thromboplastin generation test. Acta haemat. (Basel) 12: 197 1954;
• (9) Duke W. W. The relationship of blood platelets to haemorrhagic disease. Description of a method for determining the bleeding time and coagulation time and report of three cases of haemorrhagic disease relived by transfusion. J. Amer. med. Ass. 55: 1185 1910;
• (10) Fletcher A. P, Alkjaersig N. The maintenance of sustained thrombolytic state in man. J. clin. Invest. 38: 1096 1959;
• (11) Frick P. G. Acquired circulating anticoagulants in systemic “collagen disease”. Blood 10: 691 1955;
• (12) Grabar P, Williams C. Méthode immuno-électrophorétique d’analyse de mélanges de substances antigéniques. Biochim. biophys. Acta 27: 67 1955;
• (13) Hargraves M. M. The LE cell phenomenon. Proc. Mayo Clin. 27: 419 1952;
• (14) Harvey A. M, Shulman L. E, Tumulty P. A, Conley C. L, Schoenrich E. H. Systemic lupus erythematosus: review of the literature and clinical analysis of 138 cases. Medicine (Baltimore) 33: 291 1954;
• (15) Innerfield L, Goldbloom A. A, Boyd L. J. Plasma antithrombin elevation in buccal varidase treated patients. Surgery 43: 956 1958;
• (16) Kaulla K. N, Swan H, Kaulla E. Beobachtungen von Gerinnung und Fibrinolyse während chirurgischer Eingriffe am menschlichen Herzen in Unterkühlung oder mittels extrakorporalen Kreislaufes. Klin. Wschr. 36: 1050 1958;
• (17) Koller F, Loeliger A, Duckert F. Experiments on a new clotting factor (Factor VII). Acta haemat. (Basel) 6: 1 1951;
• (18) Kopec M, Niewiarowski S. Czynnosc fibrinolityczna osocza osób zdrowych. Pol. Arch. Med. Wewnet. 26: 1322 1956;
• (20) Kowarzyk H, Buluk K. Postçpy. Hig. Med. dosw. 2: 1 1950;
• (21) Kwaan H. C, McFadzean A. J. S. The inhibition of clot lysis by corticotropin. Lancet I: 136 1956;
• (22) Lee S. L, Sauders M. Laboratory studies in systemic lupus erythematosus. Arch. Dermat. Syph. (Chicago) 73: 313 1956;
• (23) Lee S. L, Sanders M, Kahny H. M. A disorder of blood coagulation in systemic lupus erythematosus. J. clin. Invest. 34: 1814 1955;
• (24) Lee R. J, White P. D. A clinical study of the coagulation time of blood. Amer. J. med. Sei. 145: 495 1913;
• (25) Loeliger A. Prothrombin as co-factor of the circulating anticoagulant in systemic lupus erythematosus?. Thromb. Diath. haem. 3: 237 1959;
• (26) Loeliger A, Hers J. F. Chronic antithrombinaemia (antithrombin V) with haemorrhagic diathesis in case of rheumatoid arthritis with hypergammaglobulinaemia. Thromb. Diath. haem. 1: 499 1957;
• (27) Meacham G. C, Weisgerber A. S. Unusual manifestations of disseminated lupus erythematosus. Ann. intern. Med. 43: 143 1956;
• (28) Michael S. R, Vural I. L, Bassen F. A, Schaefer L. The hematologic aspects of disseminated (systemic) lupus erythematosus. Blood 6: 1059 1951;
• (29) Niewiarowski S, Kowalski E. Un nouvel anticoagulant dérivé du fibrinogène. Rev. Hémat. 13: 320 1958;
• (30) Niewiarowski S, Kowalski E, Stachurska J. Influence of fibrinogen derived antithrombin (antithrombin VI) on the blood coagulation system. Acta biochim pol. 6: 43 1959;
• (31) Quick A. J. Hemorrhagic diseases. Philadelphia: 1957
• (32) Ramot C, Singer K. An unusual circulating anticoagulant m systemic lupus erythematosus. Acta haemat. (Basel) 16: 158 1956;
• (33) Sanchez Medal L, Liskier R. Circulating anticoagulants in disseminated lupus erythematosus. Brit. J. Haemat. 5: 284 1959;
• (34) Santa R. D, Verniory R, Rousso C, Vienet M, Merminod A. Présence d’un anticoagulant dans le sang d’une malade atteinte, de lupus erythémateux. Schweiz. med. Wschr. 40: 1031 1959;
• (35) Sharp A. A, Howe B, Biggs R. Defibrination syndrome in pregnancy. Lancet II: 1309 1958;
• (36) Soulier T. P. Les inhibiteurs naturels de la coagulation. Sang 30: 262 1959;
• (37) Soulier J. P, Larrieu M. J. Nouvelle méthode de diagnostic de l’hémophilie: dosage de facteurs antihémophiliques A et B. Sang 24: 205 1953;
• (38) Swift S. A serum anticoagulant factor in systemic lupus erythematosus. Arch. Dermat. Syph. (Chicago) 74: 296 1956;
• (39) Ungar G. Thrombosis and stress. Role of fibrinolytic system. 421 Intern. Conferenc on Thrombosis and Embolism; Basel: 1954
• (40) Wolf P. A modification for routine laboratory use of Stefanini s method lor estimation of Factor V in human oxalated plasma. J. clin. Path. 6: 34 1953;
• (41) Zimmer F. E, Hargraves M. M. The effect of blood coagulation on the LE cell formation. Proc. Mayo Clin. 27: 424 1952;